C1q inhibitor (chondroitin-4-sulfate proteoglycan): structure and function
- PMID: 8172570
C1q inhibitor (chondroitin-4-sulfate proteoglycan): structure and function
Abstract
The serum C1q inhibitor (C1q INH) is a chondroitin 4-sulfate proteoglycan which is composed of several polyanionic components ranging in size from 21-750 kDa. Although the activity of C1q INH has been described in terms of its ability to precipitate C1q and inhibit its hemolytic activity, not much is known about either the mechanisms of its action or its role in health and disease. This report provides evidence that a 30 kDa core protein component of the proteoglycan macromolecule contains most of the C1q inhibitory activity. This inhibitory activity occurs as a result of C1q INH binding to the C1q "heads" (gC1q) as well as to the collagen "tail" (cC1q). What may be more significant in terms of perpetuation of inflammatory processes is the ability of C1q INH to moderately activate the classical pathway leading to C2 and C4 consumption. The binding of C1q INH to C1q is enhanced at low ionic strength, but significant binding does occur under physiologic conditions which makes it likely for the inhibitor to participate in inflammatory processes especially in microenvironments of high inhibitor concentration. Such elevated concentration does occur in patients with active rheumatoid arthritis and systemic lupus erythematosus either as a result of unregulated proteoglycan synthesis or disturbances in connective tissue metabolism. Another important function of serum C1q INH is its ability to prolong the clotting time of plasma and fibrinogen solutions containing or lacking CaCl2. This potent anticoagulant activity is again displayed by the 30 kDa putative protein core which specifically binds to both the E and D domains of fibrinogen. However, the epitope(s) on the 30 kDa which binds to C1q appears to be distinct from that which binds to fibrinogen. The known presence of proteoglycans on the basement membranes and other sites may explain at least in part the presence of fibrinogen in atheromatous lesions. Furthermore, by binding to fibrinogen, soluble C1q INH-and C1q-C1q INH complexes may limit fibrin gelation in inflammatory and tissue repair microenvironments.
Similar articles
-
Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1.J Immunol. 1997 Feb 1;158(3):1324-31. J Immunol. 1997. PMID: 9013976
-
The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex.J Immunol. 1992 Dec 1;149(11):3695-701. J Immunol. 1992. PMID: 1431141
-
The receptor for the globular "heads" of C1q, gC1q-R, binds to fibrinogen/fibrin and impairs its polymerization.Clin Immunol. 1999 Mar;90(3):360-7. doi: 10.1006/clim.1998.4660. Clin Immunol. 1999. PMID: 10075865
-
C1 subcomponent complexes: basic and clinical aspects.Behring Inst Mitt. 1993 Dec;(93):292-8. Behring Inst Mitt. 1993. PMID: 8172579 Review.
-
cC1q-R (calreticulin) and gC1q-R/p33: ubiquitously expressed multi-ligand binding cellular proteins involved in inflammation and infection.Mol Immunol. 2004 Jun;41(2-3):173-83. doi: 10.1016/j.molimm.2004.03.014. Mol Immunol. 2004. PMID: 15159063 Review.
Cited by
-
Structural and functional anatomy of the globular domain of complement protein C1q.Immunol Lett. 2004 Sep;95(2):113-28. doi: 10.1016/j.imlet.2004.06.015. Immunol Lett. 2004. PMID: 15388251 Free PMC article. Review.
-
Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets.J Thromb Haemost. 2008 Aug;6(8):1413-21. doi: 10.1111/j.1538-7836.2008.03034.x. Epub 2008 May 22. J Thromb Haemost. 2008. PMID: 18503629 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous